Dan-Victor Giurgiutiu

Dan-Victor Giurgiutiu

Auto-generated profile, based on publicly available information

Dan-Victor Giurgiutiu

Vascular and Interventional Neurology, Wellstar MCG Health, Augusta, GA (D.V.G.).

Research Focus & Metrics

Academic Career Length

25Years (2002-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2019 in The Lancet Neurology
Verified
Journal Article
Closed access
DDDominique Deplanque
Dominique Deplanque
CMCharles B L M Majoie
Charles B L M Majoie
BMBijoy K Menon
Bijoy K Menon
YNYassi Nawaf
Yassi Nawaf
GSGagan Sharma
Gagan Sharma
JCJames Cunningham
James Cunningham

1 October 2018 in The Lancet Neurology
Verified
Journal Article
Closed access
ARAránzazu Román-San-Miguel
Aránzazu Román-San-Miguel
BMBijoy K Menon
Bijoy K Menon
JBJordi Blasco
Jordi Blasco
MHMaría Hernández-Pérez
María Hernández-Pérez
ADAntoni Dávalos
Antoni Dávalos
JCJames Cunningham
James Cunningham

1 January 2018 in The Lancet Neurology
Verified
Journal Article
Open access
BCBruce C V Campbell
Bruce C V Campbell
MGMayank Goyal
Mayank Goyal
BMBijoy K Menon
Bijoy K Menon
DDDiederik W J Dippel
Diederik W J Dippel
ADAndrew M Demchuk
Andrew M Demchuk
JCJames Cunningham
James Cunningham
General anaesthesia (GA) during endovascular thrombectomy has been associated with worse patient outcomes in observational studies compared with patients treated without GA. We assessed functional outcome in ischaemic stroke patients with large vessel anterior circulation occlusion undergoing endovascular thrombectomy under GA, versus thrombectomy not under GA (with or without sedation) versus standard care (ie, no thrombectomy), stratified by the use of GA versus standard care. For this meta-analysis, patient-level data were pooled from all patients included in randomised trials in PuMed published between Jan 1, 2010, and May 31, 2017, that compared endovascular thrombectomy predominantly done with stent retrievers with standard care in anterior circulation ischaemic stroke patients (HERMES Collaboration). The primary outcome was functional outcome assessed by ordinal analysis of the modified Rankin scale (mRS) at 90 days in the GA and non-GA subgroups of patients treated with endovascular therapy versus those patients treated with standard care, adjusted for baseline prognostic variables. To account for between-trial variance we used mixed-effects modelling with a random effect for trials incorporated in all models. Bias was assessed using the Cochrane method. The meta-analysis was prospectively designed, but not registered. Seven trials were identified by our search; of 1764 patients included in these trials, 871 were allocated to endovascular thrombectomy and 893 were assigned standard care. After exclusion of 74 patients (72 did not undergo the procedure and two had missing data on anaesthetic strategy), 236 (30%) of 797 patients who had endovascular procedures were treated under GA. At baseline, patients receiving GA were younger and had a shorter delay between stroke onset and randomisation but they had similar pre-treatment clinical severity compared with patients who did not have GA. Endovascular thrombectomy improved functional outcome at 3 months both in patients who had GA (adjusted common odds ratio (cOR) 1·52, 95% CI 1·09-2·11, p=0·014) and in those who did not have GA (adjusted cOR 2·33, 95% CI 1·75-3·10, p<0·0001) versus standard care. However, outcomes were significantly better for patients who did not receive GA versus those who received GA (covariate-adjusted cOR 1·53, 95% CI 1·14-2·04, p=0·0044). The risk of bias and variability between studies was assessed to be low. Worse outcomes after endovascular thrombectomy were associated with GA, after adjustment for baseline prognostic variables. These data support avoidance of GA whenever possible. The procedure did, however, remain effective versus standard care in patients treated under GA, indicating that treatment should not be withheld in those who require anaesthesia for medical reasons. Medtronic.

5 April 2016 in Journal of NeuroInterventional Surgery
Verified
Journal Article
Closed access
PDF file
AAAmin Aghaebrahim
Amin Aghaebrahim
CSChristopher Streib
Christopher Streib
SRSrikant Rangaraju
Srikant Rangaraju
CKCynthia L Kenmuir
Cynthia L Kenmuir
DGDan-Victor Giurgiutiu
Dan-Victor Giurgiutiu
AJAshutosh P Jadhav
Ashutosh P Jadhav
Background In acute stroke due to large vessel occlusion, faster reperfusion leads to better outcomes. We analyzed the effect of optimization steps aimed to reduce treatment delays at our center. Methods Consecutive patients with ischemic stroke treated with endovascular therapy were prospectively analyzed. We divided the patients into pre-optimization (20 April 2012 to 8 October 2013) and post-optimization (9 October 2013 to 29 July 2014) periods. The main interventions included: (1) continuous feedback; (2) standardized immediate emergency department attending to stroke attending communication with interventional team activation for all potential interventions; (3) pre-notification by the emergency medical service; (4) minimizing additional diagnostic testing; (5) direct transport to the CT scanner; (6) transport directly from the CT scanner to the angiography suite. The main metric used to measure improvement was door to groin puncture time (D2P). Results We included a total of 286 patients (178 pre-optimization, 108 post-optimization). There were no significant differences between major baseline characteristics between the groups with the exception of higher median CT Alberta Stroke Program Early CT Score in the pre-optimization group (p=0.01). Median D2P improved from 105 min pre-optimization to 67 min post-optimization (p=0.0002). Rates of good clinical outcomes (modified Rankin Scale 0–2 at 3 months) were similar in both groups, with a trend toward a better outcome in the post-optimization group in a subgroup analysis of patients with anterior circulation occlusion who received intravenous tissue plasminogen activator. Conclusions This pilot study demonstrates that D2P times can be significantly reduced with a standardized multidisciplinary approach. There was no significant difference in the rate of 3-month good outcome, which is most likely due to the small sample size and confounding baseline patient characteristics.

10 April 2014 in Journal of NeuroInterventional Surgery
Verified
Journal Article
Closed access
PDF file
DGDan-Victor Giurgiutiu
Dan-Victor Giurgiutiu
AYAlbert J Yoo
Albert J Yoo
KFKaitlin Fitzpatrick
Kaitlin Fitzpatrick
ZCZeshan Chaudhry
Zeshan Chaudhry
TLThabele Leslie-Mazwi
Thabele Leslie-Mazwi
NRNatalia S Rost
Natalia S Rost
Background and purpose Leukoaraiosis (LA) is defined as ischemic white matter lesions associated with increased stroke risk and poor post-stroke outcomes. These lesions are likely the result of diffuse angiopathic changes affecting the cerebral small vessels. We investigated whether pre-existing LA burden is associated with outcomes in patients with large cerebral artery occlusion undergoing intra-arterial therapy (IAT) for acute ischemic stroke (AIS). Methods We analyzed consecutive AIS subjects undergoing IAT from the institutional Get With The Guidelines-Stroke database enrolled between January 1, 2007 and June 30, 2009, who had National Institutes of Health Stroke Scale scores of ≥8, baseline diffusion weighted imaging volume ≤100 mL, and evidence of proximal artery occlusion (PAO) on pre-IAT computed tomography angiography (CTA). LA volume (LAv) was assessed on fluid attenuated inversion recovery MRI using a validated semi-automated protocol. We used CTA for collateral grade, post-IAT angiogram for recanalization status (Thrombolysis in Cerebral Infarction score ≥2b), and the 24 h head CT for symptomatic intracranial hemorrhage. Logistic regression was used to determine independent predictors of 90 day post-stroke good functional outcome (modified Rankin Scale score ≤2) and mortality. Results Increasing LAv independently reduced the odds of good collateral grade (OR 0.85, 95% CI 0.73 to 0.98). Good functional outcome was independently predicted by intravenous tissue plasminogen activator use (OR 12.86, 95% CI 2.20 to 76.28), and recanalization status (OR 6.94, 95% CI 1.56 to 30.86). Mortality was independently associated with recanalization status (OR 0.08, 95% CI 0.01 to 0.51), age (OR 1.08, 95% CI 1.01 to 1.15), and antecedent use of hypoglycemic agents (OR 6.55, 95% CI 1.58 to 54.01). Conclusions Severity of LA is linked to poor collateral grade in AIS patients undergoing IAT for PAO; however, greater LAv appears not to be a contraindication for acute intervention.

1 August 2003 in Eukaryotic Cell
Verified
Journal Article
Open access
PDF file
DBDebra A. Brock
Debra A. Brock
RHR. Diane Hatton
R. Diane Hatton
DGDan-Victor Giurgiutiu
Dan-Victor Giurgiutiu
BSBrenton Scott
Brenton Scott
WJWonhee Jang
Wonhee Jang
Richard H GomerRichard H Gomer
Richard H Gomer
Developing Dictyostelium cells aggregate to form fruiting bodies containing typically 2 × 10 4 cells. To prevent the formation of an excessively large fruiting body, streams of aggregating cells break up into groups if there are too many cells. The breakup is regulated by a secreted complex of polypeptides called counting factor (CF). Countin and CF50 are two of the components of CF. Disrupting the expression of either of these proteins results in cells secreting very little detectable CF activity, and as a result, aggregation streams remain intact and form large fruiting bodies, which invariably collapse. We find that disrupting the gene encoding a third protein present in crude CF, CF45-1, also results in the formation of large groups when cells are grown with bacteria on agar plates and then starve. However, unlike countin − and cf50 − cells, cf45-1 − cells sometimes form smaller groups than wild-type cells when the cells are starved on filter pads. The predicted amino acid sequence of CF45-1 has some similarity to that of lysozyme, but recombinant CF45-1 has no detectable lysozyme activity. In the exudates from starved cells, CF45-1 is present in a ∼450-kDa fraction that also contains countin and CF50, suggesting that it is part of a complex. Recombinant CF45-1 decreases group size in colonies of cf45-1 − cells with a 50% effective concentration (EC 50 ) of ∼8 ng/ml and in colonies of wild-type and cf50 − cells with an EC 50 of ∼40 ng/ml. Like countin − and cf50 − cells, cf45-1 − cells have high levels of cytosolic glucose, high cell-cell adhesion, and low cell motility. Together, the data suggest that CF45-1 participates in group size regulation in Dictyostelium .